Dr. Russell Greig - Chairman of the Board

Russell worked at GlaxoSmithKline (GSK) for nearly three decades, most recently as President of SR One, GSK's Corporate Venture Group...

View Profile

Geert-Jan Mulder, MD

Geert-Jan Mulder, MD, co-founded Forbion in 2006 and currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in bluebirdbio...

View Profile

Edwin de Graaf

Edwin de Graaf is a managing partner of Gilde Healthcare. He led Gilde’s investments in GlycArt (trade sale to Roche), IDEA (license to Alpharma Pharmaceuticals), Omegatech (trade sale to Martek Biosciences, now DSM), Pieris, Prosonix, Santaris Pharma (trade sale to Roche) and uniQure (IPO on NASDAQ)...

View Profile

Klaus Breiner, MA, PhD

Klaus is a venture capital investor with BB Biotech Ventures at Bellevue Group. Klaus has invested in numerous emerging biotech and pharma companies, in both the US and Europe...

View Profile

Guido Magni, MD, PhD

Dr Guido Magni was trained as an MD with a specialization in neuropharmacology. He was previously the global head of the medical science department of Roche Pharmaceuticals...

View Profile

Ashok Dhanrajgir, MBA

Ashok has more than 20 years of international healthcare experience, focused primarily on Corporate & Business Development, Mergers & Acquisitions and Strategic Planning within leading multinational corporations...

View Profile

Rémi Droller, MSc

Rémi joined Kurma Life Science Partners in September 2010. Previously he held positions at CDC Innovation and at AGF Private Equity (now Idinvest Partners)...

View Profile

Joël Jean-Mairet, PhD

Joël is a partner and co-founder of Ysios Capital Partners. He has been Chairman of the board of Cellerix since 2007 and Board Observer at Boston-based Biovex Inc. (now: Amgen)...

View Profile